- Conditions
- Whiplash Injury of Cervical Spine, Muscle Weakness
- Interventions
- Not listed
- Lead sponsor
- D'Youville College
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Tallahassee, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Attention-Deficit/Hyperactivity Disorder (Combined-subtype)
- Interventions
- Working memory training, Functional magnetic resonance imaging (fMRI)
- Behavioral · Device
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- ADHD, Fibromyalgia
- Interventions
- TD-9855
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Neurocognitive Deficit, Mental Health Impairment, Neurofibromatosis 1
- Interventions
- OPTIMAL-SSI
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- ADHD
- Interventions
- OROS-Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Seattle, Washington
- Conditions
- Attention Deficit Hyperactivity Disorder Symptoms
- Interventions
- Implementation Resource Package for Caregivers
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
- Conditions
- Weight Loss, Muscle Loss, Bone Loss
- Interventions
- Dietary Protein Intake
- Other
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years to 42 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Grand Forks, North Dakota
- Conditions
- Attention Deficit Hyperactivity Disorder Symptoms
- Interventions
- Positive Behavior Management Toolkit
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pervasive Development Disorders
- Interventions
- placebo, extended-release guanfacine
- Other · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- OPDC-34712, Placebo, Stimulant Therapy
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ankle Sprains
- Interventions
- SMART Intervention, Standard of Care Intervention
- Other
- Lead sponsor
- Phillip Gribble
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Chapel Hill, North Carolina
- Conditions
- Neurofibromatosis 1
- Interventions
- N-Acetyl cysteine, Placebo
- Drug · Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
- Interventions
- NMES Feedback, Visual Feedback, TESS
- Device
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Other · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Childhood Cancer
- Interventions
- Highlighting Patients at Risk for Sensory Screening (HPARSS)
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders, Substance-Related Disorders
- Interventions
- Placebo, Dextroamphetamine SR
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- high dose clonidine HCl sustained release, low dose clonidine HCl sustained release, placebo
- Drug
- Lead sponsor
- Addrenex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 9 more
- Conditions
- Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders
- Interventions
- methylphenidate, guanfacine
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
- Conditions
- Neuromuscular Deficits, Musculoskeletal Deficits
- Interventions
- whole body vibration using a Galileo vibrating platform
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- Methylphenidate Hydrochloride Extended Release Capsule, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate Transdermal System
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 4
- Interventions
- Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)
- Device
- Lead sponsor
- Marco Capogrosso
- Other
- Eligibility
- 16 Years to 64 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania